Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco2 cell

De Maria, Salvatore; Scognamiglio, Ilaria; Lombardi, Angela; Amodio, Nicola; Caraglia, Michele; Cartenì, Maria; Ravagnan, Gianpietro; Stiuso, Paola
November 2013
Journal of Translational Medicine;2013, Vol. 11 Issue 1, p1
Academic Journal
Background Human colon adenocarcinoma cells are resistant to chemotherapeutic agents, such as anthracyclines, that induce death by increasing the reactive oxygen species. A number of studies have been focused on chemo-preventive use of resveratrol as antioxidant against cardiovascular diseases, aging and cancer. While resveratrol cytotoxic action was due to its pro-oxidant properties. In this study, we investigate whether the Resveratrol (trans-3,5,49- trihydroxystilbene) and its natural precursor Polydatin (resveratrol-3-O-b-mono- D-glucoside, the glycoside form of resveratrol) combination, might have a cooperative antitumor effect on either growing or differentiated human adenocarcinoma colon cancer cells. Methods The polydatin and resveratrol pharmacological interaction was evaluated in vitro on growing and differentiated Caco-2 cell lines by median drug effect analysis calculating a combination index with CalcuSyn software. We have selected a synergistic combination and we have evaluated its effect on the biological and molecular mechanisms of cell death. Results Simultaneous exposure to polydatin and resveratrol produced synergistic antiproliferative effects compared with single compound treatment. We demonstrated that polydatin alone or in combination with resveratrol at 3:1 molar ratio synergistically modulated oxidative stress, cell cycle, differentiation and apoptosis. Worthy of note treatment with polydatin induced a nuclear localization and decreased expression of heat shock protein 27, and vimentin redistributed within the cell. Conclusions From morphological, and biochemical outcome we obtained evidences that polydatin induced a transition from a proliferative morphology to cell-specific differentiated structures and caused human CaCo-2 cell death by induction of apoptosis. Our data suggest the potential use of polydatin in combination chemotherapy for human colon cancer.


Related Articles

  • Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Lee, D-W; Han, S-W; Lee, H J; Rhee, Y-Y; Bae, J M; Cho, N-Y; Lee, K-H; Kim, T-Y; Oh, D-Y; Im, S-A; Bang, Y-J; Jeong, S-Y; Park, K J; Park, J-G; Kang, G H // British Journal of Cancer;5/21/2013, Vol. 108 Issue 10, p1978 

    Background:There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear.Methods:Stage II and III colorectal cancer patients who underwent...

  • Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. Volante, Marco; Marci, Valerio; Andrejevic-Blant, Snezana; Tavaglione, Veronica; Sculli, Maria; Tampellini, Marco; Papotti, Mauro; Sculli, Maria Carla // Virchows Archiv;Nov2010, Vol. 457 Issue 5, p521 

    Neuroendocrine differentiation has been described in rectal adenocarcinomas receiving neoadjuvant therapy prior to radical surgery, but its clinical relevance is controversial and no data are currently available in colorectal carcinoma metastases as compared to primary tumors. The presence of...

  • Predictors of recurrence free survival for patients with stage II and III colon cancer. Tsikitis, Vassiliki L.; Larson, David W.; Huebner, Marianne; Lohse, Christine M.; Thompson, Patricia A. // BMC Cancer;2014, Vol. 14 Issue 1, p21 

    Background The aim of this study was to evaluate clinico-pathologic specific predictors of recurrence for stage II/III disease. Improving recurrence prediction for resected stage II/III colon cancer patients could alter surveillance strategies, providing opportunities for more informed use of...

  • Survival from colorectal cancer in Germany in the early 21st century. Majek, O; Gondos, A; Jansen, L; Emrich, K; Holleczek, B; Katalinic, A; Nennecke, A; Eberle, A; Brenner, H // British Journal of Cancer;5/22/2012, Vol. 106 Issue 11, p1875 

    Background:Colorectal cancer is the most common cancer in Germany and the second most common cause of cancer-related deaths in both men and women. The aim of this study is to provide detailed analysis of recent developments in survival of colorectal cancer patients using newly available data on...

  • Does young age influence the prognosis of colorectal cancer: a population-based analysis. McKay, Andrew; Donaleshen, Jeniva; Helewa, Ramzi M.; Park, Jason; Wirtzfeld, Debrah; Hochman, David; Singh, Harminder; Turner, Donna // World Journal of Surgical Oncology;2014, Vol. 12 Issue 1, p1 

    Background Controversy exists whether young patients diagnosed with colorectal cancer have a poorer prognosis. Although younger patients are more likely to have certain poor prognostic factors, prior studies have shown mixed results in terms of overall prognosis, which may be due to lack of...

  • Prognostic significance of peritoneal lavage cytology in patients with colorectal cancer. Kobayashi, Hirotoshi; Kotake, Kenjiro; Sugihara, Kenichi // International Journal of Clinical Oncology;Jun2013, Vol. 18 Issue 3, p411 

    Background: The clinical significance of peritoneal lavage cytology for patients with gastric cancer is recognized, whereas that for patients with colorectal cancer remains controversial. The present study used a nationwide registry to clarify the prognostic significance of peritoneal lavage...

  • A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Peeters, M; Strickland, A H; Lichinitser, M; Suresh, A V S; Manikhas, G; Shapiro, J; Rogowski, W; Huang, X; Wu, B; Warner, D; Jain, R; Tebbutt, N C // British Journal of Cancer;2/12/2013, Vol. 108 Issue 3, p503 

    Background:This phase 2 study evaluated trebananib (AMG 386), an investigational peptide-Fc fusion protein that neutralises the interaction between angiopoietins-1/2 and the Tie2 receptor, plus FOLFIRI as second-line treatment for patients with metastatic colorectal cancer.Methods:Patients had...

  • Chemotherapy for small-bowel Adenocarcinoma at a single institution. Mitsukuni Suenaga; Nobuyuki Mizunuma; Keisho Chin; Satoshi Matsusaka; Eiji Shinozaki; Masatoshi Oya; Masashi Ueno; Toshiharu Yamaguchi; Tetsuichiro Muto; Fumio Konishi; Kiyohiko Hatake // Surgery Today;Jan2009, Vol. 39 Issue 1, p27 

    Abstract Purpose  Small-bowel adenocarcinoma (SBA) is rare. No standard chemotherapy for this type of cancer has yet been established. At Cancer Institute Hospital (CIH), the chemotherapy regimen used for colorectal cancer is initially used for patients with SBA, followed by that used for...

  • Colon cancer 12-gene assay cost saving in the US.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p11 

    The article reports on the findings of researchers from the U.S. showing that the use of the 12-gene assay to assess recurrence risk and guide adjuvant chemotherapy use among colon cancer patients has spared patients from toxicity risks, increased quality-adjusted survival, and was cost saving.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics